NYSE:GMED - Globus Medical Stock Price, Price Target & More

$52.09 +1.01 (+1.98 %)
(As of 04/22/2018 05:02 AM ET)
Previous Close$52.09
Today's Range$50.86 - $52.18
52-Week Range$27.79 - $52.18
Volume833,642 shs
Average Volume584,722 shs
Market Capitalization$4.92 billion
P/E Ratio39.76
Dividend YieldN/A
Beta0.42

About Globus Medical (NYSE:GMED)

Globus Medical logoGlobus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address an array of spinal pathologies, anatomies, and surgical approaches. Its fusion products include a range of implant and surgical approach options to treat degenerative, deformity, tumor, and trauma conditions along the spine from the occiput to the sacrum. The company's disruptive technology products comprise products that allow for minimally invasive surgical techniques; and new treatment alternatives, including imaging, navigational, and robotic technologies, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement, and interspinous process spacer products. Its disruptive technology products also consist of regenerative biologics products, including bioactive glass-based bone void fillers and ceramic-collagen for pelvic/extremity and posterolateral spinal fusion procedures; and interventional pain management solutions, which comprise treatments for vertebral compression fractures. In addition, the company offers products for the treatment of orthopedic trauma, including compression screws, fixation plates, intramedullary nails, and external fixation systems. Further, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.

Receive GMED News and Ratings via Email

Sign-up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:GMED
CUSIP37957720
Phone610-930-1800

Debt

Debt-to-Equity RatioN/A
Current Ratio6.67%
Quick Ratio5.50%

Price-To-Earnings

Trailing P/E Ratio39.76
Forward P/E Ratio34.73
P/E Growth2.83

Sales & Book Value

Annual Sales$635.98 million
Price / Sales7.89
Cash Flow$1.8342 per share
Price / Cash28.40
Book Value$10.04 per share
Price / Book5.19

Profitability

EPS (Most Recent Fiscal Year)$1.31
Net Income$107.34 million
Net Margins16.88%
Return on Equity13.93%
Return on Assets12.59%

Miscellaneous

Employees1,500
Outstanding Shares96,380,000

How to Become a New Pot Stock Millionaire

Globus Medical (NYSE:GMED) Frequently Asked Questions

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

How were Globus Medical's earnings last quarter?

Globus Medical Inc (NYSE:GMED) announced its quarterly earnings results on Wednesday, February, 21st. The medical device company reported $0.38 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.03. The medical device company had revenue of $176.03 million for the quarter, compared to analysts' expectations of $175.50 million. Globus Medical had a net margin of 16.88% and a return on equity of 13.93%. The business's quarterly revenue was up 16.1% compared to the same quarter last year. During the same period last year, the firm posted $0.31 earnings per share. View Globus Medical's Earnings History.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Globus Medical.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY18 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of approx $1.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.50. The company issued revenue guidance of approx $690 million, compared to the consensus revenue estimate of $690.85 million.

What price target have analysts set for GMED?

11 brokers have issued 12 month target prices for Globus Medical's shares. Their forecasts range from $36.00 to $60.00. On average, they expect Globus Medical's share price to reach $49.50 in the next twelve months. View Analyst Ratings for Globus Medical.

What are Wall Street analysts saying about Globus Medical stock?

Here are some recent quotes from research analysts about Globus Medical stock:
  • 1. According to Zacks Investment Research, "Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company's products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. " (3/13/2018)
  • 2. Canaccord Genuity analysts commented, "We recently had the opportunity to host a fireside chat with Globus, as well as visit the company’s booth during the AAOS conference and came away incrementally more confident in the growth opportunities ahead of the company. Specifically, early feedback and success with the ExcelsiusGPS system reinforce our view that the robotic platform can provide a tailwind to an improving core US spine business. In trauma, we were encouraged by the early excitement around the initial product launches – including 6 recently cleared systems to complement the 5 launched at OTA back in October – which we expect to develop into a growth driver in 2019 and beyond. Net, net, while the valuation certainly reflects continued execution in 2018, we are increasingly optimistic that the improving fundamentals in the core US spine business, early success in robotics, and OUS momentum are capable of delivering continued upside to current guidance – thus supporting continued share appreciation." (3/12/2018)
  • 3. Needham & Company LLC analysts commented, "GMED’s 4Q17 revenue was consistent with its 1/9/18 preannouncement and its EPS beat consensus. Management reiterated 2018 revenue guidance of $690M and adjusted EPS guidance of $1.50. We estimate that the Emerging Technology segment drove much of the upside given the incremental revenue and negligible EPS drag. Gross margin was up 250 bps Y/Y and operating margin was up 60 bps Y/Y. We maintain our Hold rating since we believe that GMED’s valuation appropriately reflects its Emerging Technologies business’ potential." (2/22/2018)

Who are some of Globus Medical's key competitors?

Who are Globus Medical's key executives?

Globus Medical's management team includes the folowing people:
  • Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 51)
  • Mr. David M. Demski, CEO, Group Pres of Emerging Technologies & Director (Age 60)
  • Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 47)
  • Mr. David D. Davidar, Co-Founder & Director (Age 52)
  • Mr. Daniel T. Scavilla, CFO & Sr. VP (Age 53)

Has Globus Medical been receiving favorable news coverage?

News headlines about GMED stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Globus Medical earned a news impact score of 0.17 on Accern's scale. They also gave news stories about the medical device company an impact score of 46.23 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $52.09.

How big of a company is Globus Medical?

Globus Medical has a market capitalization of $4.92 billion and generates $635.98 million in revenue each year. The medical device company earns $107.34 million in net income (profit) each year or $1.31 on an earnings per share basis. Globus Medical employs 1,500 workers across the globe.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]


MarketBeat Community Rating for Globus Medical (GMED)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  342 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  624
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Globus Medical (NYSE:GMED) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Globus Medical in the last 12 months. Their average twelve-month price target is $49.50, suggesting that the stock has a possible downside of 4.97%. The high price target for GMED is $60.00 and the low price target for GMED is $36.00. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.552.552.582.38
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $49.50$48.8333$40.5714$30.5714
Price Target Upside: 4.97% downside5.25% downside9.56% downside1.33% upside

Globus Medical (NYSE:GMED) Consensus Price Target History

Price Target History for Globus Medical (NYSE:GMED)

Globus Medical (NYSE:GMED) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018BTIG ResearchReiterated RatingBuy -> Neutral$37.00LowView Rating Details
4/4/2018Needham & Company LLCUpgradeHold -> Buy$57.00MediumView Rating Details
3/28/2018Leerink SwannReiterated RatingOutperform -> Outperform$56.00 -> $60.00LowView Rating Details
3/12/2018Canaccord GenuityReiterated RatingBuy$53.00LowView Rating Details
2/22/2018OppenheimerSet Price TargetHold$49.00MediumView Rating Details
2/22/2018Morgan StanleySet Price TargetOverweight -> Buy$48.00 -> $53.00MediumView Rating Details
1/10/2018BarclaysReiterated RatingSell$36.00MediumView Rating Details
1/10/2018Wells FargoReiterated RatingOutperform$46.00 -> $51.00HighView Rating Details
11/14/2017GabelliReiterated RatingBuyN/AView Rating Details
11/10/2017Bank of AmericaUpgradeUnderperform -> NeutralN/AView Rating Details
10/19/2017Piper JaffrayReiterated RatingBuyN/AView Rating Details
2/28/2017AegisReiterated RatingBuy$31.00N/AView Rating Details
11/9/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
11/9/2016CitigroupDowngradeMarket Perform$29.00 -> $23.00N/AView Rating Details
11/9/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
7/18/2016UBSReiterated RatingBuyN/AView Rating Details
5/26/2016Goldman SachsDowngradeNeutral -> Sell$21.00N/AView Rating Details
5/4/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Globus Medical (NYSE:GMED) Earnings History and Estimates Chart

Earnings by Quarter for Globus Medical (NYSE:GMED)

Globus Medical (NYSE:GMED) Earnings Estimates

2018 EPS Consensus Estimate: $1.52
2019 EPS Consensus Estimate: $1.68
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.35$0.36$0.36
Q2 20182$0.37$0.37$0.37
Q3 20182$0.36$0.37$0.37
Q4 20182$0.42$0.44$0.43
Q1 20191$0.41$0.41$0.41
Q2 20191$0.40$0.40$0.40
Q3 20191$0.40$0.40$0.40
Q4 20191$0.47$0.47$0.47

Globus Medical (NYSE GMED) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018$0.36N/AView Earnings Details
2/21/2018Q4 2017$0.35$0.38$175.50 million$176.03 millionViewListenView Earnings Details
11/8/2017Q3 2017$0.30$0.30$150.73 million$151.74 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.30$0.32$150.94 million$152.39 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.3050$0.32$155.81 millionViewListenView Earnings Details
2/27/2017Q416$0.33$0.31$149.30 million$151.59 millionViewListenView Earnings Details
11/8/2016Q3$0.28$0.29$139.25 million$135.70 millionViewListenView Earnings Details
7/26/2016Q2$0.29$0.29$141.78 million$137.49 millionViewListenView Earnings Details
5/3/2016Q1$0.28$0.29$140.30 million$139.30 millionViewListenView Earnings Details
2/24/2016Q4$0.30$0.32$141.20 million$142.60 millionViewListenView Earnings Details
11/3/2015Q3$0.25$0.28$127.46 million$137.00 millionViewListenView Earnings Details
7/30/2015Q215$0.25$0.25$126.89 million$133.60 millionViewListenView Earnings Details
5/5/2015Q115$0.24$0.26$122.30 million$131.60 millionViewListenView Earnings Details
2/25/2015Q414$0.25$0.30$127.77 million$128.80 millionViewListenView Earnings Details
10/30/2014Q314$0.21$0.24$113.10 million$117.80 millionViewListenView Earnings Details
8/5/2014Q214$0.23$0.23$119.83 million$113.60 millionViewListenView Earnings Details
4/29/2014Q114$0.22$0.24$113.59 million$114.20 millionViewListenView Earnings Details
2/26/2014Q413$0.22$0.25$114.96 million$115.20 millionViewListenView Earnings Details
10/30/2013Q313$0.19$0.22$106.00 million$107.19 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.20$0.21$107.46 million$107.00 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.21$103.14 million$105.00 millionViewListenView Earnings Details
2/27/2013Q4 2012$0.19$0.22$99.13 million$100.50 millionViewListenView Earnings Details
11/1/2012Q312$0.19$0.18$95.32 million$94.76 millionViewN/AView Earnings Details
8/21/2012Q2 2012$0.25ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Globus Medical (NYSE:GMED) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Globus Medical (NYSE GMED) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.21%
Institutional Ownership Percentage: 65.85%
Insider Trading History for Globus Medical (NYSE:GMED)
Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Globus Medical (NYSE GMED) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2018David M DemskiCEOSell149,109$51.00$7,604,559.00192,018View SEC Filing  
4/13/2018David M DemskiCEOSell50,891$51.00$2,595,441.00152,701View SEC Filing  
4/10/2018Daniel T ScavillaVPSell100,000$50.00$5,000,000.0018,210View SEC Filing  
3/28/2018Eric SchwartzVPSell24,000$50.00$1,200,000.0024,000View SEC Filing  
12/15/2017Steven PayneCAOSell3,076$39.30$120,886.8023,847View SEC Filing  
12/13/2017Anthony L WilliamsPresidentSell15,000$38.30$574,500.0015,000View SEC Filing  
12/4/2017David D DavidarDirectorSell55,383$40.66$2,251,872.78752,236View SEC Filing  
11/9/2017A Brett MurphyInsiderSell51,449$35.00$1,800,715.0049,768View SEC Filing  
9/6/2017A Brett MurphyInsiderSell15,000$29.99$449,850.00101,217View SEC Filing  
6/5/2017Anthony L WilliamsPresidentSell16,153$31.94$515,926.8216,153View SEC Filing  
8/5/2016A Brett MurphyInsiderSell107,692$23.37$2,516,762.04190,917View SEC Filing  
1/6/2016Robert LiptakDirectorSell15,300$27.50$420,750.0026,159View SEC Filing  
1/4/2016Kurt WheelerDirectorSell255$27.50$7,012.5044,319View SEC Filing  
5/28/2015Steven PayneCAOSell3,076$25.92$79,729.92View SEC Filing  
3/19/2015David C PaulCEOSell1,922,000$25.00$48,050,000.00View SEC Filing  
1/15/2014David DemskiCOOSell96,813$20.51$1,985,634.63381,365View SEC Filing  
12/31/2013David DemskiCOOSell3,187$20.25$64,536.75478,178View SEC Filing  
12/20/2013David DemskiCOOSell50,000$19.75$987,500.00481,365View SEC Filing  
12/6/2013Robert LiptakDirectorSell25,000$19.36$484,000.0026,159View SEC Filing  
12/3/2013David DavidarVPSell75,000$19.25$1,443,750.00897,275View SEC Filing  
11/27/2013David DemskiCOOSell37,323$19.25$718,467.75531,365View SEC Filing  
11/1/2013David M DemskiCOOSell112,677$18.59$2,094,665.43View SEC Filing  
8/23/2013David DavidarVPSell7,278$18.20$132,459.60997,499View SEC Filing  
8/22/2013David DemskiCOOSell44,154$17.95$792,564.30681,365View SEC Filing  
7/5/2013David D DavidarVPSell10,000$17.15$171,500.00View SEC Filing  
7/1/2013David D DavidarVPSell20,000$16.56$331,200.00View SEC Filing  
6/26/2013David D DavidarVPSell150,000$16.71$2,506,500.00View SEC Filing  
8/8/2012David C PaulCEOSell3,039,385$11.16$33,919,536.60View SEC Filing  
8/8/2012David D DavidarVPSell166,885$11.16$1,862,436.60View SEC Filing  
8/8/2012David M DemskiCOOSell98,957$11.16$1,104,360.12View SEC Filing  
8/8/2012Kurt WheelerDirectorSell804,232$11.16$8,975,229.12View SEC Filing  
8/8/2012Steven PayneCAOSell2,305$11.16$25,723.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Globus Medical (NYSE GMED) News Headlines

Source:
DateHeadline
Globus Medical Inc (GMED) CEO Sells $7,604,559.00 in StockGlobus Medical Inc (GMED) CEO Sells $7,604,559.00 in Stock
www.americanbankingnews.com - April 20 at 7:22 PM
Globus Medical (GMED) Downgraded to Sell at Zacks Investment ResearchGlobus Medical (GMED) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 19 at 10:12 PM
Globus Medical (GMED) Lowered to "Hold" at BidaskClubGlobus Medical (GMED) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 19 at 1:22 PM
Globus Medical (GMED) Upgraded to "Hold" at Zacks Investment ResearchGlobus Medical (GMED) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:28 AM
BTIG Sees Limited Upside For Globus Medical, Downgrades To NeutralBTIG Sees Limited Upside For Globus Medical, Downgrades To Neutral
finance.yahoo.com - April 17 at 9:46 AM
Globus Medical Inc (GMED) CEO David M. Demski Sells 50,891 SharesGlobus Medical Inc (GMED) CEO David M. Demski Sells 50,891 Shares
www.americanbankingnews.com - April 16 at 7:14 PM
Globus Medicals (GMED) "Neutral" Rating Reaffirmed at BTIG ResearchGlobus Medical's (GMED) "Neutral" Rating Reaffirmed at BTIG Research
www.americanbankingnews.com - April 16 at 8:45 AM
Zacks: Analysts Anticipate Globus Medical Inc (GMED) Will Post Quarterly Sales of $167.68 MillionZacks: Analysts Anticipate Globus Medical Inc (GMED) Will Post Quarterly Sales of $167.68 Million
www.americanbankingnews.com - April 14 at 5:43 AM
Globus Medical (GMED) Stock Rating Lowered by BidaskClubGlobus Medical (GMED) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 12:49 AM
Oppenheimer Analysts Give Globus Medical (GMED) a $35.00 Price TargetOppenheimer Analysts Give Globus Medical (GMED) a $35.00 Price Target
www.americanbankingnews.com - April 13 at 8:19 PM
Globus Medical (GMED) Receives Underweight Rating from BarclaysGlobus Medical (GMED) Receives Underweight Rating from Barclays
www.americanbankingnews.com - April 12 at 3:27 PM
$0.36 Earnings Per Share Expected for Globus Medical Inc (GMED) This Quarter$0.36 Earnings Per Share Expected for Globus Medical Inc (GMED) This Quarter
www.americanbankingnews.com - April 12 at 1:15 AM
Globus Medical Inc (GMED) VP Sells $5,000,000.00 in StockGlobus Medical Inc (GMED) VP Sells $5,000,000.00 in Stock
www.americanbankingnews.com - April 11 at 7:11 PM
Globus Medical launches two new spinal implantsGlobus Medical launches two new spinal implants
seekingalpha.com - April 6 at 4:43 PM
Globus Medical Announces Launch of ELSA® Expandable Lateral Spacer SystemGlobus Medical Announces Launch of ELSA® Expandable Lateral Spacer System
globenewswire.com - April 5 at 4:29 PM
Globus Medical Announces Launch of ELSA® Expandable Lateral Spacer SystemGlobus Medical Announces Launch of ELSA® Expandable Lateral Spacer System
finance.yahoo.com - April 5 at 4:29 PM
Globus Medical (GMED) Upgraded to Buy by Needham & Company LLCGlobus Medical (GMED) Upgraded to Buy by Needham & Company LLC
www.americanbankingnews.com - April 4 at 12:49 PM
Globus Medical Inc (GMED) Given Consensus Rating of "Buy" by BrokeragesGlobus Medical Inc (GMED) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 3:22 AM
BTIG Research Reiterates Buy Rating for Globus Medical (GMED)BTIG Research Reiterates Buy Rating for Globus Medical (GMED)
www.americanbankingnews.com - March 31 at 8:16 PM
Barclays Boosts Globus Medical (GMED) Price Target to $29.00Barclays Boosts Globus Medical (GMED) Price Target to $29.00
www.americanbankingnews.com - March 31 at 5:28 PM
Globus Medical (GMED) Upgraded by Morgan Stanley to OverweightGlobus Medical (GMED) Upgraded by Morgan Stanley to Overweight
www.americanbankingnews.com - March 31 at 12:49 PM
Eric Schwartz Sells 24,000 Shares of Globus Medical Inc (GMED) StockEric Schwartz Sells 24,000 Shares of Globus Medical Inc (GMED) Stock
www.americanbankingnews.com - March 30 at 1:14 PM
FY2019 Earnings Estimate for Globus Medical Inc Issued By Leerink Swann (GMED)FY2019 Earnings Estimate for Globus Medical Inc Issued By Leerink Swann (GMED)
www.americanbankingnews.com - March 30 at 7:36 AM
Globus Medical (GMED) Rating Reiterated by Leerink SwannGlobus Medical (GMED) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - March 28 at 11:11 AM
Globus Medical Inc (GMED) Expected to Post Earnings of $0.36 Per ShareGlobus Medical Inc (GMED) Expected to Post Earnings of $0.36 Per Share
www.americanbankingnews.com - March 26 at 1:14 AM
Globus Medical (GMED) Upgraded at Zacks Investment ResearchGlobus Medical (GMED) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 25 at 10:09 AM
Globus Medical (GMED) Rating Lowered to Hold at Zacks Investment ResearchGlobus Medical (GMED) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 14 at 12:00 AM
Globus Medical (GMED) Given Buy Rating at Canaccord GenuityGlobus Medical (GMED) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - March 12 at 9:22 PM
Globus Medical Inc (GMED) Given Consensus Rating of "Buy" by AnalystsGlobus Medical Inc (GMED) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 10 at 3:54 AM
$167.68 Million in Sales Expected for Globus Medical Inc (GMED) This Quarter$167.68 Million in Sales Expected for Globus Medical Inc (GMED) This Quarter
www.americanbankingnews.com - March 10 at 2:22 AM
Head-To-Head Survey: Globus Medical (GMED) & Cardiovascular Systems (CSII)Head-To-Head Survey: Globus Medical (GMED) & Cardiovascular Systems (CSII)
www.americanbankingnews.com - March 9 at 3:45 PM
Montco medical device maker plots big push into orthopedic trauma market - Philadelphia Business JournalMontco medical device maker plots big push into orthopedic trauma market - Philadelphia Business Journal
www.bizjournals.com - March 8 at 9:46 AM
Globus Medical Enters Trauma Market - GlobeNewswire (press release)Globus Medical Enters Trauma Market - GlobeNewswire (press release)
globenewswire.com - March 8 at 9:46 AM
Montco medical device maker plots big push into orthopedic trauma marketMontco medical device maker plots big push into orthopedic trauma market
finance.yahoo.com - March 7 at 5:18 PM
Globus Medical Enters Trauma MarketGlobus Medical Enters Trauma Market
finance.yahoo.com - March 6 at 4:50 PM
Globus Medical Inc (GMED) Shares Sold by Millrace Asset Group Inc.Globus Medical Inc (GMED) Shares Sold by Millrace Asset Group Inc.
www.americanbankingnews.com - March 5 at 12:54 PM
Opko Health (OPK) in Focus: Stock Moves 6% HigherOpko Health (OPK) in Focus: Stock Moves 6% Higher
finance.yahoo.com - March 5 at 9:37 AM
Globus Medical (GMED) Rating Increased to Buy at ValuEngineGlobus Medical (GMED) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - March 4 at 5:37 PM
Teacher Retirement System of Texas Takes $1.03 Million Position in Globus Medical Inc (GMED)Teacher Retirement System of Texas Takes $1.03 Million Position in Globus Medical Inc (GMED)
www.americanbankingnews.com - March 4 at 7:06 AM
Globus Medical Inc (GMED) Stake Decreased by Bank of New York Mellon CorpGlobus Medical Inc (GMED) Stake Decreased by Bank of New York Mellon Corp
www.americanbankingnews.com - March 4 at 4:44 AM
T2 Biosystems (TTOO) & Globus Medical (GMED) Critical ComparisonT2 Biosystems (TTOO) & Globus Medical (GMED) Critical Comparison
www.americanbankingnews.com - March 2 at 5:20 PM
Schroder Investment Management Group Has $6.04 Million Stake in Globus Medical Inc (GMED)Schroder Investment Management Group Has $6.04 Million Stake in Globus Medical Inc (GMED)
www.americanbankingnews.com - March 2 at 9:58 AM
Globus Medical Inc (GMED) Stake Boosted by Swiss National BankGlobus Medical Inc (GMED) Stake Boosted by Swiss National Bank
www.americanbankingnews.com - March 1 at 5:42 PM
Godshalk Welsh Capital Management Inc. Has $2.67 Million Stake in Globus Medical Inc (GMED)Godshalk Welsh Capital Management Inc. Has $2.67 Million Stake in Globus Medical Inc (GMED)
www.americanbankingnews.com - March 1 at 4:24 PM
EAM Investors LLC Takes Position in Globus Medical Inc (GMED)EAM Investors LLC Takes Position in Globus Medical Inc (GMED)
www.americanbankingnews.com - March 1 at 12:04 PM
Globus Medical Inc (GMED) Forecasted to Post FY2021 Earnings of $1.95 Per ShareGlobus Medical Inc (GMED) Forecasted to Post FY2021 Earnings of $1.95 Per Share
www.americanbankingnews.com - February 26 at 10:08 AM
Leerink Swann Comments on Globus Medical Incs FY2018 Earnings (GMED)Leerink Swann Comments on Globus Medical Inc's FY2018 Earnings (GMED)
www.americanbankingnews.com - February 26 at 6:44 AM
Equities Analysts Offer Predictions for Globus Medical Incs Q1 2018 Earnings (GMED)Equities Analysts Offer Predictions for Globus Medical Inc's Q1 2018 Earnings (GMED)
www.americanbankingnews.com - February 26 at 2:40 AM
Globus Medical Inc (GMED) Position Increased by Schwab Charles Investment Management Inc.Globus Medical Inc (GMED) Position Increased by Schwab Charles Investment Management Inc.
www.americanbankingnews.com - February 25 at 5:38 AM
Columbia Partners L L C Investment Management Has $3.14 Million Position in Globus Medical Inc (GMED)Columbia Partners L L C Investment Management Has $3.14 Million Position in Globus Medical Inc (GMED)
www.americanbankingnews.com - February 24 at 4:20 PM

SEC Filings

Globus Medical (NYSE:GMED) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Globus Medical (NYSE:GMED) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Globus Medical (NYSE GMED) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.